Clinical trials: Doxorubicin Induced Cardiomyopathy, open to volunteers
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Breast cancer is one of the world's most common cancers in females. Most of the chemotherapy protocols used to treat breast cancer involve doxorubicin. Doxorubicin has a very significant antitumor effect on breast tumors.
- Conditions
- Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy, Doxorubicin, Doxorubicin Adverse Reaction
- Trial name
- NICBREASTRCT (NCT07897409)
- Testing
- Nicorandil Oral Tablet, Adriamycin (Doxorubicin)
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Universiti Sains Malaysia
Doxorubicin Induced Cardiomyopathy, Breast Cancer
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
This is a randomized controlled clinical trial that aims to evaluate the safety and efficacy of Dapagliflozin as a cardioprotective in doxorubicin-induced cardiotoxicity in breast cancer patients.
- Trial name
- NCT06427226
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Tanta University
Breast Cancer, Doxorubicin Induced Cardiomyopathy
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing…
- Trial name
- NCT07370506
- Testing
- Telmisartan, Doxorubicin (DOX)
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Tanta University